Bessemer Group’s Genomic Health, Inc. GHDX Stock Holding History

Bessemer Group’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,070	Closed	-$26K	–	1527
2016 Q1	$26K	Buy	+1,070	New	+$29.4K	﹤0.01%	1016
2014 Q3	–	Sell	-719	Closed	-$20K	–	1446
2014 Q2	$20K	Buy	+719	New	+$19.1K	﹤0.01%	1021

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bessemer Group's GHDX Position: Q2 2016 in Review

Bessemer Group sold out of Genomic Health, Inc. (GHDX) in Q2 2016, closing a stake of 1,070 shares — an estimated $26K sold.

Bessemer Group first reported a position in GHDX in Q2 2014 and held it in 2 quarters. The position peaked at $26K in Q1 2016. 130 funds tracked by Wall St. Rank hold GHDX as of Q2 2016.

Bessemer Group reported no remaining Genomic Health, Inc. position as of Q2 2016 after selling out during the quarter.
Bessemer Group sold 1,070 Genomic Health, Inc. shares in Q2 2016, an estimated $26K.
Bessemer Group first reported a position in Genomic Health, Inc. in Q2 2014 and held it in 2 quarters.
Bessemer Group's Genomic Health, Inc. position peaked at $26K in Q1 2016.
130 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.